Immunoproteasome Inhibitor–Doxorubicin Conjugates Target Multiple Myeloma Cells and Release Doxorubicin upon Low-Dose Photon Irradiation

[Image: see text] Proteasome inhibitors are established therapeutic agents for the treatment of hematological cancers, as are anthracyclines such as doxorubicin. We here present a new drug targeting approach that combines both drug classes into a single molecule. Doxorubicin was conjugated to an imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Maurits, Elmer, van de Graaff, Michel J., Maiorana, Santina, Wander, Dennis P. A., Dekker, Patrick M., van der Zanden, Sabina Y., Florea, Bogdan I., Neefjes, Jacques J. C., Overkleeft, Herman S., van Kasteren, Sander I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181259/
https://www.ncbi.nlm.nih.gov/pubmed/32275401
http://dx.doi.org/10.1021/jacs.9b11969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181259/
https://www.ncbi.nlm.nih.gov/pubmed/32275401
http://dx.doi.org/10.1021/jacs.9b11969

Ejemplares similares